Authorized purpose: NAEOTOM Alpha.Peak, Alpha, Alpha.Pro, and Alpha.Prime are photon-counting CT systems for diagnostic cross-sectional imaging, treatment and interventional support, low-dose lung-cancer screening under approved protocols, and radiation-therapy planning.
Clinical role
Photon-counting CT acquisition, reconstruction, spectral imaging, diagnostic review, and model-supported treatment or radiation-planning imaging.
Images and patients
CT/CTA · Multi-region
Key limitation
Keep in mind: The scanner is not the principal guidance method for invasive procedures. Model, field of view, temporal resolution, spectral function, reconstruction, and radiotherapy support must be matched to the exact system and software.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: NAEOTOM Alpha.Peak, Alpha, Alpha.Pro, and Alpha.Prime are photon-counting CT systems for diagnostic cross-sectional imaging, treatment and interventional support, low-dose lung-cancer screening under approved protocols, and radiation-therapy planning.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Multi-region Input: X-ray projection data acquired using model- and protocol-specific photon-counting detector configurations.
Who uses it?Intended users: Qualified CT technologists and physicians trained in diagnostic, interventional, or radiation-therapy CT workflows.
What does the software produce?Output: Cross-sectional CT images, spectral or quantitative image sets, and planning-support images.
What is its most important limitation?Key limitation: The scanner is not the principal guidance method for invasive procedures. Model, field of view, temporal resolution, spectral function, reconstruction, and radiotherapy support must be matched to the exact system and software.
Clinical takeaway. Clinical role: NAEOTOM Alpha.Peak, Alpha, Alpha.Pro, and Alpha.Prime are photon-counting CT systems for diagnostic cross-sectional imaging, treatment and interventional support, low-dose lung-cancer screening under approved protocols, and radiation-therapy planning.
Evidence takeaway. Evidence from the reviewed source record: K243523 describes manufacturer system, image-quality, dose, spectral, reconstruction, and workflow verification and explicitly includes radiation-therapy planning. Peer-reviewed photon-counting CT literature is technology-level evidence and does not prove outcomes for every listed model.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
NAEOTOM Alpha.Peak, Alpha, Alpha.Pro, and Alpha.Prime are photon-counting CT systems for diagnostic cross-sectional imaging, treatment and interventional support, low-dose lung-cancer screening under approved protocols, and radiation-therapy planning.
The scanner is not the principal guidance method for invasive procedures. Model, field of view, temporal resolution, spectral function, reconstruction, and radiotherapy support must be matched to the exact system and software.
K243523 describes manufacturer system, image-quality, dose, spectral, reconstruction, and workflow verification and explicitly includes radiation-therapy planning. Peer-reviewed photon-counting CT literature is technology-level evidence and does not prove outcomes for every listed model.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
K243523 describes manufacturer system, image-quality, dose, spectral, reconstruction, and workflow verification and explicitly includes radiation-therapy planning. Peer-reviewed photon-counting CT literature is technology-level evidence and does not prove outcomes for every listed model.
Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.
Reported specificity
Not applicable
Not applicable
Exact FDA submission
Checked 2026-09-04
Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K243523 FDA performance package for NAEOTOM Alpha.Peak/ NAEOTOM Alpha; NAEOTOM Alpha.Pro; NAEOTOM Alpha.Prime
K243523 FDA evidence package for NAEOTOM Alpha.Peak/ NAEOTOM Alpha; NAEOTOM Alpha.Pro; NAEOTOM Alpha.Prime
DesignFDA 510(k) verification and validation evidence described in the exact submission
PopulationMulti-region
Scopeexact submission
Tested versionNAEOTOM Alpha.Peak/Alpha/Alpha.Pro/Alpha.Prime with syngo CT VB20
IndependenceSponsor or vendor study
K243523
Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the device within the applicable imaging or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: X-ray projection data acquired using model- and protocol-specific photon-counting detector configurations.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Installed photon-counting CT system with syngo CT VB20 and model-specific gantry, detector, reconstruction, siting, and service configuration.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Cross-sectional CT images, spectral or quantitative image sets, and planning-support images.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.
Only qualified ct technologists and physicians trained in diagnostic, interventional, or radiation-therapy ct workflows. should operate or interpret the system. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: The scanner is not the principal guidance method for invasive procedures. Model, field of view, temporal resolution, spectral function, reconstruction, and radiotherapy support must be matched to the exact system and software.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The scanner is not the principal guidance method for invasive procedures. Model, field of view, temporal resolution, spectral function, reconstruction, and radiotherapy support must be matched to the exact system and software.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
Vendor productivity claims are scenario inputs, not guaranteed local savings.
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: The scanner is not the principal guidance method for invasive procedures. Model, field of view, temporal resolution, spectral function, reconstruction, and radiotherapy support must be matched to the exact system and software.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
25Fields reviewed
12Source classes checked
20Screened PubMed leads
8Screened trial leads
0Unreviewed FDA recall leads
Screened 20 PubMed titles and eight trial records. NCT07016477 names the NAEOTOM Alpha family but not the K243523 syngo CT VB20 configuration; all 28 candidates lack exact tested-version linkage and are quarantined. The current discovery snapshot contains 20 PubMed and 8 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, vendor product page, peer reviewed publication, reimbursement policy, fda device recall, fda decision material, peer reviewed literature, clinical trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
CT 5300 acquires head and whole-body cross-sectional CT images for diagnosis in adult and pediatric patients and supports low-dose lung-cancer screening under approved protocols.
Authorized purpose: NAEOTOM Alpha with syngo CT VB10 provides photon-counting CT for diagnosis, treatment and interventional support, and approved low-dose lung screening; this submission explicitly does not support radiation-therapy planning.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.